Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.

Wang S, Oh DY, Leventaki V, Drakos E, Zhang R, Sahin AA, Resetkova E, Edgerton ME, Wu W, Claret FX.

Cancer Lett. 2019 Nov 28;465:12-23. doi: 10.1016/j.canlet.2019.08.016. Epub 2019 Aug 29.

2.

HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.

Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA.

Hum Pathol. 2019 Jul 24;92:32-38. doi: 10.1016/j.humpath.2019.07.006. [Epub ahead of print]

PMID:
31351155
3.

The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer.

Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y.

J Cancer. 2019 Jun 2;10(12):2635-2642. doi: 10.7150/jca.32453. eCollection 2019.

4.

Sphingosine Kinase 1 Signaling Promotes Metastasis of Triple-Negative Breast Cancer.

Acharya S, Yao J, Li P, Zhang C, Lowery FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, Piwnica-Worms H, Sahin AA, Yu D.

Cancer Res. 2019 Aug 15;79(16):4211-4226. doi: 10.1158/0008-5472.CAN-18-3803. Epub 2019 Jun 25.

PMID:
31239273
5.

Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression.

Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L.

Nat Immunol. 2019 Jul;20(7):835-851. doi: 10.1038/s41590-019-0400-7. Epub 2019 Jun 3.

PMID:
31160797
6.

Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.

Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP.

Cancers (Basel). 2019 May 29;11(6). pii: E754. doi: 10.3390/cancers11060754.

7.

Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers.

Sahin AA, Gilligan TD, Caudell JJ.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):560-564. doi: 10.6004/jnccn.2019.5015.

PMID:
31117030
8.

Effects of tranexamic acid on the recovery of osteochondral defects treated by microfracture and acellular matrix scaffold: an experimental study.

Degirmenci E, Ozturan KE, Sahin AA, Yilmaz F, Kaya YE.

J Orthop Surg Res. 2019 Apr 15;14(1):105. doi: 10.1186/s13018-019-1144-7.

9.

Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor.

Adhikary S, Chakravarti D, Terranova C, Sengupta I, Maitituoheti M, Dasgupta A, Srivastava DK, Ma J, Raman AT, Tarco E, Sahin AA, Bassett R, Yang F, Tapia C, Roy S, Rai K, Das C.

Nat Commun. 2019 Mar 28;10(1):1398. doi: 10.1038/s41467-019-08986-5.

10.

Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery.

Park KU, Kuerer HM, Rauch GM, Leung JWT, Sahin AA, Wei W, Li Y, Black DM.

Ann Surg Oncol. 2019 Jun;26(6):1720-1728. doi: 10.1245/s10434-019-07226-w. Epub 2019 Mar 14.

PMID:
30877499
11.

Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.

Neely C, You S, Mendoza PM, Aneja R, Sahin AA, Li X.

Breast J. 2018 Nov;24(6):889-893. doi: 10.1111/tbj.13110. Epub 2018 Sep 19.

PMID:
30230095
12.

Evaluation of right atrial volumes and functions by real-time three-dimensional echocardiography in patients after acute inferior myocardial infarction.

Kanar BG, Sunbul M, Sahin AA, Dogan Z, Tigen MK.

Echocardiography. 2018 Nov;35(11):1806-1811. doi: 10.1111/echo.14133. Epub 2018 Sep 7.

PMID:
30192408
13.

Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins.

Tevis SE, Neuman HB, Mittendorf EA, Kuerer HM, Bedrosian I, DeSnyder SM, Thompson AM, Black DM, Scoggins ME, Sahin AA, Hunt KK, Caudle AS.

Ann Surg Oncol. 2018 Oct;25(10):2932-2938. doi: 10.1245/s10434-018-6607-2. Epub 2018 Jun 26.

14.

Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy.

Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):568-577. doi: 10.1016/j.ijrobp.2018.06.016. Epub 2018 Jun 19.

PMID:
29928946
15.

The effect of geographical and climatic properties on grass pollen and Phl p 5 allergen release.

Alan Ş, Şahin AA, Sarışahin T, Şahin S, Kaplan A, Pınar NM.

Int J Biometeorol. 2018 Jul;62(7):1325-1337. doi: 10.1007/s00484-018-1536-0. Epub 2018 Apr 6.

PMID:
29626255
16.

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.

Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC.

Cancer Cell. 2018 Feb 12;33(2):187-201.e10. doi: 10.1016/j.ccell.2018.01.009.

17.

Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score.

Meisel J, Zhang C, Neely C, Mendoza P, You S, Han T, Liu Y, Sahin AA, O'Regan R, Li X.

Clin Breast Cancer. 2018 Oct;18(5):347-352. doi: 10.1016/j.clbc.2017.12.006. Epub 2017 Dec 14.

PMID:
29305309
18.

Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.

Fujii T, Matsuda N, Kono M, Harano K, Chen H, Luthra R, Roy-Chowdhuri S, Sahin AA, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT.

Eur J Cancer. 2018 Jan;89:64-71. doi: 10.1016/j.ejca.2017.11.015. Epub 2017 Dec 9.

PMID:
29232568
19.

Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.

Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, Hoffman K, Adrade B, Sahin AA, Kuerer HM, Hunt KK, Caudle AS.

Clin Breast Cancer. 2018 Aug;18(4):276-281. doi: 10.1016/j.clbc.2017.10.007. Epub 2017 Oct 13.

20.

Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.

Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, Tripathy D, Iwamoto T, Hunt KK, Pusztai L, Lim B, Shen Y, Ueno NT.

Ann Oncol. 2017 Oct 1;28(10):2420-2428. doi: 10.1093/annonc/mdx397.

21.

African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.

Arciero CA, Yang J, Peng L, Ward KC, O'Regan R, Sahin AA, Li X.

Breast Cancer Res Treat. 2017 Dec;166(3):743-755. doi: 10.1007/s10549-017-4484-1. Epub 2017 Aug 30.

PMID:
28856481
22.

Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells.

Daquinag AC, Dadbin A, Snyder B, Wang X, Sahin AA, Ueno NT, Kolonin MG.

Mol Ther Oncolytics. 2017 May 17;6:1-9. doi: 10.1016/j.omto.2017.05.003. eCollection 2017 Sep 15.

23.

Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience.

Atas H, Sahin AA, Barutçu Atas D, Sunbul M, Kepez A, Agirbasli M.

Clin Appl Thromb Hemost. 2018 Apr;24(3):536-541. doi: 10.1177/1076029617695484. Epub 2017 Mar 1.

24.

Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy.

Fujii T, Kogawa T, Wu J, Sahin AA, Liu DD, Chavez-MacGregor M, Giordano SH, Raghavendra A, Murthy RK, Tripathy D, Shen Y, Yamal JM, Ueno NT.

Br J Cancer. 2017 Feb 14;116(4):509-514. doi: 10.1038/bjc.2016.444. Epub 2017 Jan 12.

25.

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.

Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL.

Breast Cancer Res Treat. 2017 Jan;161(2):279-287. doi: 10.1007/s10549-016-4059-6. Epub 2016 Nov 25.

PMID:
27888421
26.

Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.

Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K.

Clin Cancer Res. 2017 Jun 15;23(12):2991-3002. doi: 10.1158/1078-0432.CCR-16-2217. Epub 2016 Nov 23.

27.

Deubiquitination and Stabilization of PD-L1 by CSN5.

Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC.

Cancer Cell. 2016 Dec 12;30(6):925-939. doi: 10.1016/j.ccell.2016.10.010. Epub 2016 Nov 17.

28.

Clinical outcomes based on multigene profiling in metastatic breast cancer patients.

Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F.

Oncotarget. 2016 Nov 22;7(47):76362-76373. doi: 10.18632/oncotarget.12987.

29.

Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer.

Treekitkarnmongkol W, Katayama H, Kai K, Sasai K, Jones JC, Wang J, Shen L, Sahin AA, Gagea M, Ueno NT, Creighton CJ, Sen S.

Carcinogenesis. 2016 Dec;37(12):1180-1189. Epub 2016 Sep 13.

30.

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.

Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Ding Q, Wang Y, Yao J, Lee CC, Wu HJ, Sahin AA, Allison JP, Yu D, Hortobagyi GN, Hung MC.

Nat Commun. 2016 Aug 30;7:12632. doi: 10.1038/ncomms12632.

31.

Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K.

Am J Pathol. 2016 Jul;186(7):1900-1912. doi: 10.1016/j.ajpath.2016.02.024. Epub 2016 May 13.

32.

High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.

Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin AA, Welm A, Oesterreich S, Sikora MJ, Brown RE, Mills GB.

Clin Cancer Res. 2016 Oct 15;22(20):5068-5078. Epub 2016 May 12.

33.
34.

The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment.

Mittendorf EA, Vila J, Tucker SL, Chavez-MacGregor M, Smith BD, Symmans WF, Sahin AA, Hortobagyi GN, Hunt KK.

JAMA Oncol. 2016 Jul 1;2(7):929-36. doi: 10.1001/jamaoncol.2015.6478.

35.

Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy.

Mougalian SS, Hernandez M, Lei X, Lynch S, Kuerer HM, Symmans WF, Theriault RL, Fornage BD, Hsu L, Buchholz TA, Sahin AA, Hunt KK, Yang WT, Hortobagyi GN, Valero V.

JAMA Oncol. 2016 Apr;2(4):508-16. doi: 10.1001/jamaoncol.2015.4935.

36.

Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.

Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D.

Nature. 2015 Nov 5;527(7576):100-104. doi: 10.1038/nature15376. Epub 2015 Oct 19.

37.

Histopathological Features of Non-Neoplastic Breast Parenchyma Do Not Predict BRCA Mutation Status of Patients with Invasive Breast Cancer.

Bayraktar S, Qiu H, Liu D, Shen Y, Gutierrez-Barrera AM, Arun BK, Sahin AA.

Biomark Cancer. 2015 Aug 18;7:39-49. doi: 10.4137/BIC.S29716. eCollection 2015.

38.

A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.

Abba MC, Gong T, Lu Y, Lee J, Zhong Y, Lacunza E, Butti M, Takata Y, Gaddis S, Shen J, Estecio MR, Sahin AA, Aldaz CM.

Cancer Res. 2015 Sep 15;75(18):3980-90. doi: 10.1158/0008-5472.CAN-15-0506. Epub 2015 Aug 6.

39.

Biobanking in genomic medicine.

Zhou JH, Sahin AA, Myers JN.

Arch Pathol Lab Med. 2015 Jun;139(6):812-8. doi: 10.5858/arpa.2014-0261-RA. Review.

40.

Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.

Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK.

Oncologist. 2015 May;20(5):466-73. doi: 10.1634/theoncologist.2014-0107. Epub 2015 Mar 23.

41.

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.

Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F.

J Natl Cancer Inst. 2015 Feb 16;107(3). pii: dju493. doi: 10.1093/jnci/dju493. Print 2015 Mar.

42.

14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2.

Xu J, Acharya S, Sahin O, Zhang Q, Saito Y, Yao J, Wang H, Li P, Zhang L, Lowery FJ, Kuo WL, Xiao Y, Ensor J, Sahin AA, Zhang XH, Hung MC, Zhang JD, Yu D.

Cancer Cell. 2015 Feb 9;27(2):177-92. doi: 10.1016/j.ccell.2014.11.025.

43.

Evaluation of the stage IB designation of the American Joint Committee on Cancer staging system in breast cancer.

Mittendorf EA, Ballman KV, McCall LM, Yi M, Sahin AA, Bedrosian I, Hansen N, Gabram S, Hurd T, Giuliano AE, Hunt KK.

J Clin Oncol. 2015 Apr 1;33(10):1119-27. doi: 10.1200/JCO.2014.57.2958. Epub 2014 Dec 8.

44.

Breast pathology second review identifies clinically significant discrepancies in over 10% of patients.

Khazai L, Middleton LP, Goktepe N, Liu BT, Sahin AA.

J Surg Oncol. 2015 Feb;111(2):192-7. doi: 10.1002/jso.23788. Epub 2014 Oct 1.

PMID:
25273328
45.

Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer.

Zhou JH, Rosen D, Andreou A, Brouquet A, Abbott D, Loyer E, Gonzalez-Angulo AM, Kopetz S, Meric-Bernstam F, Kuerer H, Abdalla E, Vauthey JN, Sahin AA, Maru DM.

Ann Diagn Pathol. 2014 Oct;18(5):266-70. doi: 10.1016/j.anndiagpath.2014.07.001. Epub 2014 Jul 17.

46.

Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.

Pande M, Bondy ML, Do KA, Sahin AA, Ying J, Mills GB, Thompson PA, Brewster AM.

Breast Cancer Res Treat. 2014 Sep;147(2):381-7. doi: 10.1007/s10549-014-3081-9. Epub 2014 Aug 10.

47.

Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.

Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC.

Cancer Res. 2014 Sep 1;74(17):4822-35. doi: 10.1158/0008-5472.CAN-14-0584. Epub 2014 Jun 26.

48.
49.

Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.

Ordóñez NG, Sahin AA.

Hum Pathol. 2014 Jul;45(7):1529-40. doi: 10.1016/j.humpath.2014.03.006. Epub 2014 Mar 27.

PMID:
24816068
50.

Too much, too little, or just right? Tumor margins in women undergoing breast-conserving surgery.

Hunt KK, Sahin AA.

J Clin Oncol. 2014 May 10;32(14):1401-6. doi: 10.1200/JCO.2013.54.8388. Epub 2014 Mar 31. No abstract available.

PMID:
24687821

Supplemental Content

Loading ...
Support Center